Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study
NCT ID: NCT07097805
Last Updated: 2025-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
3000 participants
INTERVENTIONAL
2025-01-01
2028-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a multicenter, prospective, cohort study. This longitudinal investigation systematically collects multidimensional clinical datasets encompassing glycemic control parameters, pancreatic β-cell function, and complication risk profiles through regular follow-up visits. This study explores the metabolic control, psychological outcomes, and their associated influencing factors among patients with T1D.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
T1D Patients
All patients diagnosed with type 1 diabetes of all ages.
GLITTER comprehensive management
The GLITTER comprehensive management represents a management approach that effectively combines multidisciplinary professional team care, diabetes technology empowerment, structured education steering, and peer support.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GLITTER comprehensive management
The GLITTER comprehensive management represents a management approach that effectively combines multidisciplinary professional team care, diabetes technology empowerment, structured education steering, and peer support.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
The diagnosis criteria for type 1 diabetes are met by fulfilling any one point from the first two criteria plus any one point from the third criterion.
1. Clinically diagnosed as Type 1 Diabetes by a specialist physician.
2. Meet any one of the following criteria:
A. Age of onset \<15 years B. No obesity at the time of onset C. diabetic ketoacidosis onset D. Maximum random C-peptide \<200 pmol/L
3. Meet any one of the following criteria:
A. Initiation and continuation of insulin therapy after diagnosis (excluding pancreas or islet transplantation) B. Positive for islet cell antibodies
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xia Li
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Endocrinology and Metabolism, Peking University People's Hospital
Beijing, Beijing Municipality, China
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Department of Endocrinology and Metabolism, the Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong, China
Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, China
Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University
Changsha, Hunan, China
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University
Chengdu, Sichuan, China
Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaoling Cai
Role: primary
Chang Liu
Role: primary
Jinhua Yan
Role: primary
Haiyan Li
Role: primary
Hongwei Jiang
Role: primary
Xia Li
Role: primary
Mei Zhang
Role: primary
Yanli Cao
Role: primary
Nanwei Tong
Role: primary
Junfen Fu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KYZ20240193
Identifier Type: -
Identifier Source: org_study_id